Atea Pharmaceuticals AVIR

$ 3.29 5.11%

Quarterly report 2024-Q3
added 11-07-2024

Atea Pharmaceuticals Balance Sheet 2011-2024 | AVIR

Annual Balance Sheet Atea Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-141 M	-185 M	-	-	-21.7 M	-34.5 M	-	-	-	-	-	-	-
Long Term Debt	1.64 M	2.4 M	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	760 K	721 K	197 K	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	69.2 M	69.3 M	-	-	-	-	-	-	-
Total Current Liabilities	32.4 M	18.5 M	56.9 M	316 M	-	-	-	-	-	-	-	-	-
Total Liabilities	39.8 M	26.1 M	62.8 M	316 M	71.6 M	71 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-196 M	-59.9 M	56 M	-65.2 M	-54.2 M	-40.2 M	-	-	-	-	-	-	-
Total Assets	595 M	667 M	773 M	864 M	22.1 M	34.9 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	144 M	188 M	764 M	850 M	21.7 M	34.6 M	-	-	-	-	-	-	-
Book Value	555 M	641 M	710 M	548 M	-49.6 M	-36.2 M	-	-	-	-	-	-	-
Total Shareholders Equity	555 M	641 M	710 M	548 M	-49.6 M	-36.2 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Atea Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	1.04 M	1.24 M	1.44 M	1.64 M	1.84 M	2.03 M	2.22 M	2.4 M	2.58 M	2.77 M	2.76 M	-	-	29 K	114 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	32.4 M	33.9 M	48.7 M	39.8 M	26.3 M	23.7 M	19.9 M	26.1 M	23.4 M	33.9 M	37.3 M	62.8 M	262 M	274 M	254 M	316 M	316 M	316 M	316 M	2.53 M	2.53 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	192 M	225 M	235 M	301 M	301 M	301 M	301 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-331 M	-300 M	-259 M	-196 M	-157 M	-124 M	-95.3 M	-59.9 M	-25.4 M	-17.4 M	14 M	56 M	-61.1 M	-32.9 M	-34.4 M	-65.2 M	-65.2 M	-65.2 M	-65.2 M	-54.2 M	-54.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	491 M	510 M	553 M	595 M	608 M	626 M	638 M	667 M	687 M	694 M	717 M	773 M	844 M	872 M	841 M	864 M	864 M	864 M	864 M	22.1 M	22.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	98.5 M	243 M	161 M	144 M	138 M	214 M	183 M	188 M	176 M	684 M	706 M	764 M	840 M	816 M	834 M	850 M	850 M	850 M	850 M	21.7 M	21.7 M	-	-	34.5 M	-	-	-	15 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	459 M	476 M	504 M	555 M	582 M	602 M	618 M	641 M	663 M	660 M	680 M	710 M	581 M	598 M	586 M	548 M	548 M	548 M	548 M	19.5 M	19.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	459 M	476 M	504 M	555 M	582 M	602 M	618 M	641 M	663 M	660 M	680 M	710 M	581 M	598 M	586 M	548 M	548 M	548 M	548 M	-49.6 M	-49.6 M	-41.6 M	-38.2 M	-36.2 M	-	-	-	-27.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency